Enanta Q2 net loss $31.2M; cash $300.3M; RSV data readouts expected in 2H 2024

ENANTA PHARMACEUTICALS INC

2024-Q2 EPS reported -$3.06 revenue$35,057,000

Fiscal Q2 2024 revenue $17.1M (AbbVie HCV royalty); net loss $31.2M ($1.47 loss/share) vs $37.7M loss a year ago.
Cash, equivalents, and marketable securities total $300.3M; expected runway through Q3 FY2027.
Zelicapavir Phase 2 pediatric RSV data expected 2H 2024; EDP-323 challenge study data expected Q3 2024.
KIT inhibitor development candidate for CSU targeted Q4 2024; second immunology program planned in 2024.
Expense guidance updated: R&D $125M-$145M, G&A $50M-$60M due to immunology/RSV efforts and Pfizer patent lawsuit.

item 2.02 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.95

ENANTA PHARMACEUTICALS INC reported fiscal quarter ended March 31, 2024 results: revenue $17.1 million, EPS a loss of $1.47 per diluted common share. Guidance reaffirmed.

Period: fiscal quarter ended March 31, 2024
Revenue: $17.1 million
EPS: a loss of $1.47 per diluted common share
Guidance: reaffirmed
Result: reported results

Exact text from the filing

chronic diseases with a second program this year.” Fiscal Second Quarter Ended March 31, 2024 Financial Results Total revenue for the three months ended March 31, 2024 was $17.1 million and consisted of royalty revenue from worldwide net sales of AbbVie’s hepatitis C virus (HCV) regimen MAVYRET®/MAVIRET® (glecaprevir/pibrentasvir), compared to $17.8 million for

View on SEC.gov

710 earnings releases filed in the last 30 days. Browse all earnings releases →

ENANTA PHARMACEUTICALS INC filing history →

Source: SEC EDGAR

accession 0000950170-24-053532

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.